Premium
MR spectroscopy in monitoring the treatment of Wilson's disease patients
Author(s) -
Tarnacka Beata,
Szeszkowski Wojciech,
Golebiowski Marek,
Czlonkowska Anna
Publication year - 2008
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22163
Subject(s) - exacerbation , medicine , gastroenterology , globus pallidus , basal ganglia , central nervous system
The aim of this study was to determine the effectiveness of brain proton magnetic resonance spectroscopy ( 1 H‐MRS) for monitoring therapy in Wilson's disease (WD) patients. Voxels were located in the globus pallidus (right, left). We followed 17 newly diagnosed WD cases for 1‐year period. During this observation period, 6 neurological and 9 hepatic patients improved, while 2 neurological patients deteriorated. The pretreatment 1 H‐MRS analysis showed a statistically significant lower level of mI/Cr, NAA/Cr, and higher Lip/Cr in all WD patients with improvement compared with controls. In patients with hepatic signs, a statistically significant increase of mI/Cr and Glx/Cr was observed in the second (1 year posttreatment) 1 H‐MRS. In patients with neurological improvement after treatment in the follow‐up 1 H‐MRS, a statistically significant increase of NAA/Cr was noted. During neurological deterioration, a decrease of Glx/Cr and NAA/Cr was seen, in contrast to another neurologically impaired patient with liver failure exacerbation, where a decrease of mI/Cr and increase of Glx/Cr was observed. The alternations of NAA/Cr ratio in neurologically impaired patients and mI/Cr and Glx/Cr in patients with liver failure could be a sensitive marker of the clinical recovery and deterioration in those WD patients. 1 H‐MRS is a technique that can be used for accurate monitoring of treatment efficacy in WD patients. © 2008 Movement Disorder Society